Author

Ding Yu

Observed name: Yu Ding

Institutions: Tianjin Anding Hospital, Tianjin Medical University

Observed institutions: China National Pharmaceutical Group Corporation (China), Tianjin Anding Hospital, China National Biotechnology (China), Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Hubei Cancer Hospital, Huazhong University of Science and Technology, Tianjin Medical University, Southern Medical University

ORCID: 0009-0004-6920-4009

Observed ORCID: 0009-0004-6920-4009

OpenAlex ID: A5101797591

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

2020 · Kai Duan, Bende Liu, et al. · Proceedings of the National Academy of Sciences · 1,985

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

2021 · Cesheng Li, Ding Yu, et al. · Nature Communications · 76

PDF

A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients

2021 · Sichao Wang, Zihao Zhou, et al. · Annals of Translational Medicine · 15

PDF

Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma

2022 · Ding Yu, Yu‐Feng Li, et al. · Advanced Science · 13

PDF

Surgical resection of primary tumors improved the prognosis of patients with bone metastasis of non-small cell lung cancer: a population-based and propensity score-matched study

2021 · Dan Tian, Xiaosong Ben, et al. · Annals of Translational Medicine · 12

PDF

Prevalence and Influencing Factors of Severe Depression in Nurses During and After the COVID‐19 Pandemic: A Large‐Scale Multicenter Study

2024 · Jiao Liu, Qinghe Liu, et al. · Depression and Anxiety · 9

PDF

Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial

2024 · Zhiming Li, Wenqi Jiang, et al. · Journal for ImmunoTherapy of Cancer · 8

PDF

COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan

2022 · Hong Liang, Xuanxuan Nian, et al. · Cell Discovery · 6

PDF

A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study

2025 · Minghua Hong, Dawei Ding, et al. · European Journal of Pharmacology · 5

Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID

2023 · Junzheng Wu, Huichuan Yang, et al. · MedComm · 4

Effects of Deep Transcranial Magnetic Stimulation on Cognitive Function in Bipolar Depression: A Randomized Controlled Trial Using the MATRICS Consensus Cognitive Battery

2026 · Lijun Chu, Xiaoju Jia, et al. · ALPHA PSYCHIATRY · 1

PDF

Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study

2024 · Chunkang Chang, Min Zhang, et al. · Blood · 1

PDF

Pd34-04 Exosomes Induce the Regeneration of Corpus Spongiosum in Urethral Reconstruction in Rabbits

2025 · Fang Chen, Yichen Huang, et al. · The Journal of Urology

PDF

Research progress of liquid biopsy in early diagnosis of lung cancer

2019 · Ding Yu, Qiao Guibin · Guoji zhongliuxue zazhi

Screening the Proteins Interacted With Ns38 in Grass Carp Reovirus by Yeast Two-hybrid System

2013 · Li Jie, Yan Xiu-ying, et al. · Haiyang yu huzhao

Works count: 15

Citation count: 2,135

H-index: 7

I10-index: 5